Stilo Giovanna, Messina Giuliano, Lo Faro Carmelo, Ruta Sara, Frangipane Silvia, Mariut Diana, Giunta Giorgia, Distefano Maria Elvira, Zappalà Andrea Guglielmo, Maniaci Antonino, Bianchi Alberto, La Mantia Ignazio
Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", ENT Section, University of Catania, Via Santa Sofia, 95100 Catania, Italy.
Department of General Surgery and Surgical-Medical Specialties, Section of Maxillo Facial Surgery of Polyclinic "G. Rodolico-San Marco" University Hospital, University of Catania, 95123 Catania, Italy.
J Pers Med. 2025 Apr 24;15(5):164. doi: 10.3390/jpm15050164.
: Olfactory recovery plays an important role in improving the quality of life in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP), and Dupilumab therapy shows promising results. The Nasal Polyp Score (NPS), Visual Analog Scale (VAS) for olfactory disorders (ODs), and the Sniffin' Sticks 16-item identification test (SS-I) are three of the main indices of efficacy in CRSwNP treatment. Although mechanical obstruction appears to be a major cause of olfactory disorders in this condition, the three indices can often vary with different trends. Aim: The aim is to assess whether there is a correlation between the sense of smell recovery and the volumetric reduction in polyps and to assess how the reduction in NPS affects the improvement in olfactory symptoms. : An observational monocentric retrospective cohort study was conducted on a sample of 50 patients, enrolled in treatment with Dupilumab for 12 months at the ENT Unit of Rodolico Hospital. We investigated the relationship between NPS changes and olfactory recovery using the Sniffin' Stick 16-item identification test and the VAS for ODs at baseline and follow-up endpoints (1-, 3-, 6-, 9-, and 12-month assessments). : During the follow-up, according to the data in the literature, the patients showed a faster improvement in terms of SS-I and VAS for ODs than expressed in terms of NPS variation. : This study shows that, in patients treated with Dupilumab, there is no strong correlation between the reduction in NPS and the recovery of the sense of smell evaluated by an improvement in the SS-I and VAS for ODs in the 12 months of follow-up, suggesting that, in patients with CRSwNP, the improvement in olfactory symptoms following treatment with Dupilumab is mainly related to its anti-inflammatory effects and not to the reduction in mechanical obstruction caused by nasal polyps.
嗅觉恢复对改善慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）患者的生活质量起着重要作用，度普利尤单抗治疗显示出有前景的结果。鼻息肉评分（NPS）、嗅觉障碍（ODs）视觉模拟量表（VAS）以及嗅觉棒16项识别测试（SS-I）是CRSwNP治疗中三个主要的疗效指标。尽管机械性阻塞似乎是这种情况下嗅觉障碍的主要原因，但这三个指标的变化趋势往往不同。目的：评估嗅觉恢复与息肉体积缩小之间是否存在相关性，并评估NPS的降低如何影响嗅觉症状的改善。：对在罗多利科医院耳鼻喉科接受度普利尤单抗治疗12个月的50例患者样本进行了一项单中心观察性回顾性队列研究。我们在基线和随访终点（1、3、6、9和12个月评估）使用嗅觉棒16项识别测试和ODs的VAS来研究NPS变化与嗅觉恢复之间的关系。：在随访期间，根据文献数据，患者在SS-I和ODs的VAS方面的改善比NPS变化所显示的更快。：本研究表明，在接受度普利尤单抗治疗的患者中，在12个月的随访中，NPS的降低与通过SS-I和ODs的VAS改善所评估的嗅觉恢复之间没有很强的相关性，这表明，在CRSwNP患者中，度普利尤单抗治疗后嗅觉症状的改善主要与其抗炎作用有关，而不是与鼻息肉引起的机械性阻塞的减轻有关。
